EP1235580A2 - Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine - Google Patents

Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine

Info

Publication number
EP1235580A2
EP1235580A2 EP00987336A EP00987336A EP1235580A2 EP 1235580 A2 EP1235580 A2 EP 1235580A2 EP 00987336 A EP00987336 A EP 00987336A EP 00987336 A EP00987336 A EP 00987336A EP 1235580 A2 EP1235580 A2 EP 1235580A2
Authority
EP
European Patent Office
Prior art keywords
acetylsalicylic acid
tts
migraine
treatment
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00987336A
Other languages
German (de)
English (en)
Inventor
Hanshermann Franke
Bodo Asmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of EP1235580A2 publication Critical patent/EP1235580A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Transdermal system for the treatment of migraines containing acetylsalicylic acid.
  • the present invention relates to the use of acetylsalicylic acid for the treatment of migraines and other serotonin-dependent, platelet-mediated diseases, the administration of the active ingredient taking place transdermally.
  • the invention encompasses processes in which acetylsalicylic acid is administered to the human skin by a transdermal therapeutic system for the purpose of prophylactic treatment of the migraine.
  • the invention further relates to the use of acetylsalicylic acid for the production of transdermal therapeutic systems for migraine prophylaxis, and transdermal therapeutic systems containing acetylsalicylic acid which are suitable for migraine prophylaxis.
  • Migraines are a multifactorial occurrence, triggered by different exogenous and endogenous causes.
  • the underlying biochemical processes are largely known, although the pathophysiological processes as a whole have not been clarified.
  • a central role in migraines is attributed to the abnormal regulation of cerebral blood flow. The latter is controlled by a number of different factors, e.g. B. biogenic
  • NSAIDs non-steroidal anti-inflammatory drugs
  • serotonin antagonists serotonin antagonists
  • acetylsalicylic acid ASA
  • ASA acetylsalicylic acid
  • the use of ASA for migraine prophylaxis is based on the assumption that ASA as a prostaglandin synthesis inhibitor influences the metabolism of certain cellular blood components, especially thrombocytes, and reduces their biochemical reactivity. In this way, there can be a quantitative change in the neurotransmitters and hormones produced by these blood cells come. An increased thrombocytic serotonin release, such as occurs at the beginning of a migraine attack, could be favorably influenced by active ingredients such as ASA.
  • Oral administration of ASA has several disadvantages.
  • SS salicylic acid
  • the inhibition of platelet function - which is also important in migraine therapy - is mediated by ASA and not by SS (W. Horsch, "Die Salicylate", Pharmazie 34, 585-604, 1979). This leaves a significant portion of the dose administered unused.
  • oral administration of ASA especially if it extends over long periods, often leads to gastrointestinal side effects, e.g. B. gastric bleeding.
  • ASA-containing transdermal therapeutic systems which allow the application of ASA bypassing the gastrointestinal tract, have already been described.
  • TTS transdermal therapeutic systems
  • the last-mentioned publication primarily refers to the use in antithrombotic therapy and in colon cancer prophylaxis.
  • ASA topical or transdermal use of ASA, also in the form of ointments, gels and. the like , also described for the therapeutic treatment of various other disease states.
  • the object of the present invention was to demonstrate a method for the medicinal prophylaxis of migraines which has few side effects and is therefore suitable for long-term use, which is simple and patient-friendly to use and at the same time effective in preventing migraine conditions, but which on the other hand does not have the known disadvantages associated with oral administration of ASA.
  • acetylsalicylic acid is administered transdermally, preferably using a transdermal therapeutic system according to the invention.
  • the migraine frequency is significantly reduced. It is significant that - unlike with oral administration - the ASA level in the blood plasma remains low and does not exceed 0.5 ⁇ g / l (cf. Example 3). Average acetylsalicylic acid plasma levels of less than 10 ng / ml can be achieved during the day.
  • an increase in the trigger threshold for migraine attacks was surprisingly found. Avoiding high ASA plasma levels also reduces the risk of systemic side effects.
  • average salicylate blood plasma levels of at least 20 ng / l, preferably from 100 to 400 ng / ml, can be achieved in humans during the course of the day (cf. Example 3). These values indirectly indicate a very efficient absorption of ASA through the skin.
  • the present invention provides an effective, cost-effective, low-side effect and patient- or patient- user-friendly treatment method for migraine prophylaxis.
  • the therapy method proposed by the invention is suitable for both long-term prophylaxis and one
  • Acute prophylaxis of migraines is also possible to combine the transdermal administration of TTS according to the invention with conventional migraine prophylaxis and other therapeutic regimens. Even if the present invention is primarily aimed at the treatment or prophylaxis of migraines, this does not exclude that it is also applicable to the treatment of other serotonin-dependent, platelet-mediated diseases.
  • acetylsalicylic acid is administered in combination with one or more other active substances and / or in combination with auxiliary substances.
  • Particularly suitable as further active substances are those which likewise have an analgesic effect and can be absorbed transdermally.
  • Active substances from the following groups are preferably considered for a combined administration with ASA in a TTS: serotonin antagonists, non-selective serotonin derivatives, simple analgesics, analgesic combinations, ergotamine derivatives, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, Phenothiazines, opiate analgesics, beta blockers, calcium channel blockers, tricyclic antidepressants, antiepileptics and monoamine oxidase inhibitors.
  • serotonin antagonists non-selective serotonin derivatives
  • simple analgesics simple analgesics
  • analgesic combinations ergotamine derivatives
  • non-steroidal anti-inflammatory drugs (NSAIDs) non-steroidal anti-inflammatory drugs
  • Phenothiazines corticosteroids
  • Phenothiazines Phenothiazines
  • opiate analgesics beta blockers
  • calcium channel blockers
  • the ASA-containing TTS is preferably used in such a way that the application time, based on a single TTS, is at most one week, preferably 1 to 3 days. A continuous daily application over a NEN period of at least 16 hours is particularly advantageous.
  • the amount of ASA released to the skin by the TTS within one day is preferably in a range between 1 mg and 100 mg.
  • TTS particularly suitable as TTS, which according to the invention can be used for migraine prophylaxis using the active ingredient ASS, are TTS of the matrix type, which are composed of a backing layer which is essentially impermeable to active ingredients and moisture, one or more active ingredient-containing matrix layer (s), and have a removable protective layer.
  • TTS of the matrix type which are composed of a backing layer which is essentially impermeable to active ingredients and moisture, one or more active ingredient-containing matrix layer (s), and have a removable protective layer.
  • acetylsalicylic acid is predominantly present in crystalline form in at least one of the matrix layers and in which at least part of the active ingredient acetylsalicylic acid is present in crystalline form as a stable
  • anhydrous modification which melts at above 132 ° C. can advantageously be used.
  • ASS crystals with a diameter of less than about 50-100 ⁇ m are particularly advantageous.
  • the TTS according to the invention can contain further active ingredients which have already been mentioned above. These can either be located together with acetylsalicylic acid in the same matrix layer or in one or more separate matrix layers. Embodiments are particularly preferred in which the active substances are present in at least two matrices that are separate from one another and are released at mutually independent release rates.
  • the skin permeation rates that can be achieved with the TTS according to the invention, based on ASA, are preferably in the range of 0.02-2 mg / cm 2 d, particularly preferably in the range of 0.1-0.4 mg / cm 2 d ,
  • the matrix base material of the TTS according to the invention is primarily copolymers containing acrylic acid esters, and also mixtures of rubbers and resins, polyvinyl acetate, silicone polymers and many other materials, the use of which is harmless to human skin.
  • the active ingredient-containing polymer matrix can additionally contain auxiliary substances and additives, e.g. B. fillers such as titanium dioxide, zinc oxide, chalk, activated carbon, finely divided silicon dioxide, and skin permeation-promoting additives which are known to the person skilled in the art.
  • auxiliary substances and additives e.g. B. fillers such as titanium dioxide, zinc oxide, chalk, activated carbon, finely divided silicon dioxide, and skin permeation-promoting additives which are known to the person skilled in the art.
  • liquid additives such as short-chain alcohols, triglycerides, cholesterol, cineol, delta-tocopherol, diethylene glycol, diethylene glycol monoethyl ether, diisopropyl adipate, dimethyldecylphosphoxide, dimethylisosorbide, dimethyllauroylamide, dodecylsulfoxide, ethylacetylsulfoxide, ethylacetylsulfoxide, and other ethylenethylacid sulfates and aliphatic esters, ethylene glycol, ethylene glycol monolaurate and other esters and ethers of ethylene glycol and propylene glycol, 2-octyldodecanol, low-viscosity paraffin, glycerol, glycerol monooleate, glycerol monostearate, hydrogenated castor oil, isopropyl myristate, isopropyl palmitate, lauric
  • the reactivity of the active ingredient acetylsalicylic acid with esters and acids as well as alcohols must be taken into account in individual cases, which limits the use of these substances.
  • Numerous plastic materials which are characterized by strength and diffusion resistance are suitable for the formation of the backing layer, especially polyester, polyvinyl chloride, ethylene vinyl acetate, vinyl acetate, polyethylene, polypropylene, cellulose dervates and many others.
  • the back layer can be vapor-coated with metals or other diffusion-blocking additives, such as silicon dioxide, aluminum oxide or the like.
  • the rear layer can also be painted skin-colored on the outside to improve acceptance, or it can be treated in some other way to improve the external appearance.
  • the removable protective layer to be removed before the application of the TTS to the skin can be made from polyester material, but also from any other plastics suitable for use on the skin, e.g. B. from polyvinyl chloride, ethylene vinyl acetate, vinyl acetate, polyethylene, polypropylene, cellulose derivatives and many others. As with the production of the backing layer, additional vapor deposition with diffusion-blocking substances can also take place in the protective layer.
  • Plastoid ® B 8.25% The details indicate the respective proportions by mass, based on the total mass of the active substance matrix.
  • the ASA release was determined using the "paddle-over-disk" method of the USP.
  • the content of acetylsalicylic acid and salicylic acid in the blood plasma was determined by GC-MS. While the acetylsalicylic acid content remained below the detection limit of 6 ng / ml at both times, the salicylic acid level was 72 ⁇ 18 ng / ml on day 10 and 157 ng / ml on day 14.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une utilisation de l'acide acétylsalicylique pour le traitement de la migraine et d'autres maladies dépendantes de la sérotonine, à médiation thrombocytaire, qui se caractérise par le fait que le principe actif est administré à l'aide d'un système thérapeutique transdermique.
EP00987336A 1999-12-11 2000-12-01 Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine Withdrawn EP1235580A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19959913 1999-12-11
DE19959913A DE19959913A1 (de) 1999-12-11 1999-12-11 Acetylsalicylsäure enthaltendes transdermales System zur Behandlung von Migräne
PCT/EP2000/012092 WO2001041771A2 (fr) 1999-12-11 2000-12-01 Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine

Publications (1)

Publication Number Publication Date
EP1235580A2 true EP1235580A2 (fr) 2002-09-04

Family

ID=7932378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00987336A Withdrawn EP1235580A2 (fr) 1999-12-11 2000-12-01 Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine

Country Status (8)

Country Link
US (1) US20030008852A1 (fr)
EP (1) EP1235580A2 (fr)
JP (1) JP2003516356A (fr)
KR (1) KR20020058087A (fr)
AU (1) AU2361801A (fr)
CA (1) CA2393748A1 (fr)
DE (1) DE19959913A1 (fr)
WO (1) WO2001041771A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5225100B2 (ja) * 2005-12-20 2013-07-03 テイコク ファーマ ユーエスエー インコーポレーテッド インドールセロトニン受容体作動薬の経皮投与方法及びそれを使用するための経皮組成物
CN102933207B (zh) 2009-10-30 2018-02-02 Ix生物医药有限公司 快速溶解固体剂型
US20140083878A1 (en) * 2012-09-21 2014-03-27 Mylan Inc. Transdermal drug delivery device
KR20160001419A (ko) * 2014-06-27 2016-01-06 포항공과대학교 산학협력단 양이온성 분자 수송체 및 음이온성 생리활성 물질을 포함하는 피부 투과용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4218445A (en) * 1978-05-08 1980-08-19 Kasthuri Thirumalachar Mandaya N,N'Dibenzylethylenediamine-diacetylsalicylate, a novel chemotherapeutic agent for pain relief by external application
US4219548A (en) * 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
US5401730A (en) * 1990-07-06 1995-03-28 The Hope Heart Institute Method for reducing platelet aggregation
DE4332093C2 (de) * 1993-09-22 1995-07-13 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Acetylsalicylsäure und Verfahren zu seiner Herstellung
DE4416927C1 (de) * 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung
GB2319473A (en) * 1995-07-27 1998-05-27 Cal Int Ltd Transdemal patch containing aspirin
US5736126A (en) * 1996-03-15 1998-04-07 Van Engelen; H. Wayne Liquid transdermal analgesic
DE19701059C2 (de) * 1997-01-15 2000-12-21 Lohmann Therapie Syst Lts Acetylsalicylsäure enthaltendes transdermales therapeutisches System mit Resorptionsverstärkung
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0141771A2 *

Also Published As

Publication number Publication date
JP2003516356A (ja) 2003-05-13
US20030008852A1 (en) 2003-01-09
WO2001041771A3 (fr) 2001-12-27
KR20020058087A (ko) 2002-07-12
DE19959913A1 (de) 2001-06-28
CA2393748A1 (fr) 2001-06-14
AU2361801A (en) 2001-06-18
WO2001041771A2 (fr) 2001-06-14

Similar Documents

Publication Publication Date Title
DE102006054731B4 (de) Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
DE4241874C2 (de) Medizinisches Pflaster für die perkutane Verabreichung des Wirkstoffs Ketoprofen
EP0617623B1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique
EP0720479B1 (fr) Systeme therapeutique transdermique contenant comme principe actif l'acide acetylsalicylique
EP0817622A1 (fr) Medicament a administration transdermique, comportant des inhibiteurs de l'enzyme de conversion de l'angiotensine
WO2002002111A1 (fr) Systeme therapeutique dermique contenant des antiphlogistiques non steroidiens a inhibition selective de la cox-2
EP1251853B1 (fr) Systeme therapeutique transdermique pour l'administration de zaleplon
WO2001026637A2 (fr) Systeme therapeutique transdermique permettant de delivrer de l'acide acetylsalicylique et/ou de l'acide salicylique
EP1235580A2 (fr) Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine
EP1171105B1 (fr) Systeme therapeutique transdermique contenant un neuroleptique tres actif
EP0742716B1 (fr) Composition pharmaceutique pour administration transdermique systemique contenant du morphine-6-glucoronide comme principe actif
DE19949252B4 (de) Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
WO2002069941A1 (fr) Système thérapeutique transdermique pour l'administration d'agonistes partiels de la dopamine d2
DE10340428A1 (de) Opioides Analgetikum enthaltende transdermale Formulierung
AT504040B1 (de) Diclofenac-hältige zubereitung zur behandlung von verbrennungen
DE10025971B4 (de) Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung
EP0671916A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer
EP0659079B1 (fr) Systeme therapeutique percutane contenant du pentylenetetrazol comme principe actif
WO2001089511A2 (fr) Systeme therapeutique superficiel contenant de l'acide acetylsalicylique pour le traitement de douleurs cutanees
WO1994013302A1 (fr) Systeme d'administration transdermique contenant de l'acide acetylsalicylique pour la therapie antithrombotique et la prophylaxie contre le cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FRANKE, HANSHERMANN

Inventor name: ASMUSSEN, BODO

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040616